Analyst recommendations for UnitedHealth Group
UnitedHealth Group (UNH) is the leading health insurance company in the United States. This managed healthcare company is focused on establishing itself as a diversified healthcare business and has been recently undertaking a number of strategic acquisitions aimed at that goal.
The company operates in two divisions—UnitedHealthcare that offers health benefits and Optum that offers technology-enabled health services. Optum operates in three segments: OptumHealth, OptumInsight, and OptumRx.
UnitedHealth Group has a market capitalization of $260 billion. In fiscal 2017, its sales were $201 billion. In the second quarter of fiscal 2018, it generated sales of $56.1 billion. It will release its third quarter of fiscal 2018 results on October 16.
In this part of the series, we’ll look at analyst recommendations and target prices for UNH ahead of the company’s third-quarter earnings release.
According to an October 10 Reuters survey of the 24 analysts covering UNH stock, ten analysts have recommended a “strong buy,” and 13 have recommended a “buy.” Only one has rated it a “hold,” and there were no “sell” ratings.
As of October 10, analysts’ 12-month target price for UnitedHealth Group stock was $292.90, implying an ~8.4% return based on its closing price of $270.45 on October . Analysts’ 12-month target prices for peers CVS Health (CVS), Anthem (ANTM), and Aetna (AET) were $88.35, $301.11, and $204.80, respectively, representing potential returns of 11.2%, 7.9%, and 0.53%, respectively.
Recommendation revisions and updates
On October 3, Jefferies increased its price target for UNH stock from $292 to $311. UNH stock registered its 52-week high that day. On September 24, Raymond James raised its target price for UNH stock from $285 to $304.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!